Oral formulations of deferasirox

Abstract

Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

What is claimed: 
     
         1 . A dosage composition for oral Administration containing deferasirox in an amount selected from the group consisting of 90 mg, 180 mg, and 360 mg, wherein the composition comprises
 (i) at least one filler in a total amount of 10% to 40% by weight based on total weight of the composition;   (ii) at least one disintegrant in a total amount of 1% to 10% by weight based on the total weight of the composition;   (iii) at least one binder in a total amount of 1% to 5% by weight based on the total weight of the composition; and, optionally, separate from the total weight of the composition; and,   (iv) a coating of the dosage composition.   
     
     
         2 . A dosage composition according to  claim 1  wherein,
 (i) filler is selected from the group consisting essentially of microcrystalline cellulose, lactose, and ethylcellulose; 
 (ii) disintegrant is selected from the group consisting essentially of cross-linked polyvinylpyrrolidone (crospovidone), starch, CMC-Ca, CMC-Na, microcrystalline cellulose, alginic acid, sodium alginate, and guar gum; and, 
 (iii) binder is selected from the group consisting essentially of polyvinylpyrrolidone (PVP), hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, microcrystalline cellulose, hypromellose, and starch. 
 
     
     
         3 . A dosage composition for oral administration containing deferasirox in an amount selected from the group consisting of 90 mg, 180 mg, and 360 mg, wherein the composition comprises microcrystalline cellulose in an amount of 1% to 55% by weight based on total weight of the dosage composition. 
     
     
         4 . A dosage composition according to  claim 1  comprising,
 (i) at least one surfactant in a total amount of 0.0% to 2% by weight based on the total weight of the composition; and, 
 (ii) at least one lubricant in a total amount of less than 0.1% to 2% by weight based on the total weight of the composition. 
 
     
     
         5 . A dosage composition according to  claim 4  wherein,
 (i) surfactant is selected from the group consisting essentially of poloxamer, sodium laurel sulfate, betain, quaternary ammonium salt, polysorbate, and sorbitan ester; and, 
 (ii) lubricant is selected from the group consisting essentially of magnesium stearate, Al-stearate, Ca-stearate, PEG 4000-8000, talc, sodium benzoate, glyceryl mono fatty acid, glyceryl monostearate, glyceryl dibehenate, glyceryl palmito-stearic ester, polyoxyethylene glycol, hydrogenated cotton seed oil, and castor seed oil. 
 
     
     
         6 . A composition according to  claim 4  comprising,
 (i) about 0.1% surfactant; and, 
 (ii) less than about 0.2% lubricant. 
 
     
     
         7 . A composition according to  claim 5  comprising,
 (iv) about 0.1% poloxamer; and, 
 (vii) less than about 0.2% magnesium stearate 
 
     
     
         8 . A dosage composition for oral administration containing deferasirox in an amount selected from the group consisting of 90 mg, 180 mg, and 360 mg, wherein the composition comprises
 (i) at least one filler in a total amount of about to 10% to 40% by weight based on the total weight of the composition;   (ii) at least one disintegrant in a total amount of about 1% to 10% by weight based on the total weight of the composition;   (iii) at least one binder in a total amount of about 1% to 5% by weight based on the total weight of the composition;   (iv) at least one surfactant in a total amount of about 0.0% to 2% by weight based on the total weight of the composition; and,   (v) at least one lubricant in a total amount of less than about 0.1% to 2% by weight based on the total weight of the composition.